tiprankstipranks
Design Therapeutics (DSGN)
NASDAQ:DSGN
US Market
Holding DSGN?
Track your performance easily

Design Therapeutics (DSGN) Ownership - Who Owns Design Therapeutics?

82 Followers

Design Therapeutics (DSGN) Ownership Overview

19.36%6.36%32.97%5.41%35.90%
19.36% Insiders
32.97% Other Institutional Investors
5.41% ETFs
35.90% Public Companies and
Individual Investors
The ownership structure of Design Therapeutics (DSGN) stock is a mix of institutional, retail, and individual investors. Approximately 44.74% of the company’s stock is owned by Institutional Investors, 19.36% is owned by Insiders, and 35.90% is owned by Public Companies and Individual Investors.
The ownership structure of {name} ({ticker}) stock is a mix of institutional, retail, and individual investors. {displayInstitutionalData, select, display {Approximately {institutionalPercentage} of the company’s stock is owned by Institutional Investors} other {}}{displayInsiderText, select, display {, {insidersPercentage} is owned by Insiders} other {}}{displayInvestorsText, select, display {, and {retailInvestorsPercentage} is owned by Public Companies and Individual Investors.} other {}}

Recent Insider Trading Activity

Date
Name
Activity
Value
Aug 12, 2024
xxxxxxxxxxxxx
$3463215
Mar 25, 2024
John Schmid
Director
xxxxxxxxxxxxx
$99659
Mar 25, 2024
xxxxxxxxxxxxx
$4862

Recent Hedge Fund Trading Activity

Date
Firm
Activity
Value
Sep 30, 2024
xxxxxxxxxxxxx
$9381240

Top Shareholders

Holder
# of Shares
Type
% Holding
Value
6,526,476Insider11.53%36,352,471
4,217,627Insider7.45%23,492,182
1,743,725Institution3.08%9,712,548
1,367,021Institution2.41%7,614,307
1,233,956Institution2.18%6,873,135
1,103,406Institution1.95%6,145,971
705,900Institution1.25%3,931,863
359,435Institution0.63%2,002,053
275,438Institution0.49%1,534,190
238,799Institution0.42%1,330,110

Top Mutual Fund Holders

Holder
# of Shares
Type
% Holding
Value
1,103,406Institution1.95%6,145,971
705,900Institution1.25%3,931,863
359,435Institution0.63%2,002,053
275,438Institution0.49%1,534,190
238,799Institution0.42%1,330,110
224,300Institution0.40%1,249,351
150,003Institution0.26%835,517
143,703Institution0.25%800,426
74,915Institution0.13%417,277
54,200Institution0.10%301,894

Top ETF Holders

Holder
# of Shares
Type
% Holding
Value
853,078Institution1.51%4,751,644
800,901Institution1.41%4,196,721
399,505Institution0.71%2,093,406
296,283Institution0.52%1,650,296
141,510Institution0.25%775,475
142,814Institution0.25%748,345
72,881Institution0.13%405,947
73,147Institution0.13%400,846
55,015Institution0.10%295,981
37,412Institution0.07%205,018

FAQ

Who Owns Design Therapeutics (DSGN)?
According to the latest TipRanks data, approximately 32.97% of the company's stock is held by institutional investors, 19.36% is held by insiders, and 35.90% is held by retail investors.
    What percentage of Design Therapeutics (DSGN) stock is held by institutional investors?
    According to the latest TipRanks data, approximately 32.97% of Design Therapeutics (DSGN) stock is held by institutional investors.
      What percentage of Design Therapeutics (DSGN) stock is held by retail investors?
      According to the latest TipRanks data, approximately 35.90% of Design Therapeutics (DSGN) stock is held by retail investors.
        Who owns the most shares of Design Therapeutics (DSGN)?
        Simeon George owns the most shares of Design Therapeutics (DSGN).
          What is the significance of the ownership structure for a publicly traded company?
          The ownership structure can impact the company's decision making, as large institutional investors may exert influence on the company's management and can also affect the company's stock price with their buying and selling patterns.
            What am I Missing?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis